Cubist Pharmaceuticals, Inc. (CBST) Announces Quarterly Results, Misses Estimates By $0.77 EPS
Thursday, July 14, 2021 6:11 PM

Cubist Pharmaceuticals, Inc. (CBST) announced its quarterly results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.77. The company’s quarterly revenue was up 4.9% on a year-over-year basis.

On a related note, analysts at Wedbush reiterated an "outperform" rating on shares of Cubist Pharmaceuticals, Inc. in a research note to investors on Thursday. Also, analysts at Jefferies raised their price target on shares of Cubist Pharmaceuticals, Inc. to $44.00 in a research note to investors on Thursday, June 2nd.

Shares of Cubist Pharmaceuticals, Inc. (CBST) traded down 1.13% during mid-day trading on Thursday, hitting $35.93. Cubist Pharmaceuticals, Inc. (CBST) has a 52 week low of $20.08 and a 52 week high of $39.29. The stock's 50-day moving average is $36.13 and its 200-day moving average is $28.77. The company has a market cap of $2.154 billion and a price-to-earnings ratio of 23.52.

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. Cubist’s owns CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). During the year ended December 31, 2009, this product was used in the treatment of more than an estimated 880,000 patients. In December 2009, the Company acquired Calixa Therapeutics Inc.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement